Form 4: Guardant Health Director Steve Krognes Reports Stock Transactions

Director Steve Krognes reports acquisition and disposal of Guardant Health stock and derivative securities.

Summary

• On June 12, 2024, Steve Krognes, a director of Guardant Health, Inc., reported transactions involving the company's stock.
• Krognes acquired 5,592 shares of common stock through the exercise of restricted stock units.
• He also disposed of 9,140 shares of common stock.
• Additionally, Krognes acquired 10,703 stock options with an exercise price of $31.84, vesting fully on June 12, 2024, or the date of the next year annual stockholders meeting, whichever is earlier, and expiring on June 12, 2034.
• He also acquired 6,674 restricted stock units vesting fully on June 12, 2024, or the date of the next year annual stockholders meeting, whichever is earlier.
• Following these transactions, Krognes directly owns 10,703 stock options and 6,674 restricted stock units.

Sentiment

Score: 5

Explanation: The sentiment is neutral. There are both acquisitions and disposals of stock, making it difficult to definitively assess the director's sentiment. The acquisitions of stock options and restricted stock units could be seen as positive, but the disposal of shares tempers this view.

Positives

• The acquisition of stock options and restricted stock units by a director could be seen as a positive sign, indicating confidence in the company's future performance.

Negatives

• The disposal of 9,140 shares of common stock by a director could be interpreted negatively by some investors.

Risks

• Director stock sales can sometimes be perceived negatively by the market, potentially leading to short-term price fluctuations.

Future Outlook

The document does not contain explicit forward-looking statements, but the vesting schedules of the restricted stock units and stock options suggest a multi-year commitment from the director.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. Investors often monitor these filings for insights into management's sentiment about the company's prospects.

Comparison to Industry Standards

• Insider trading activity is a common metric used to gauge sentiment in the biotech industry.
• Comparing Krognes' transactions to those of other directors at similar companies like Exact Sciences or Illumina could provide a broader context.
• Generally, consistent buying activity by multiple insiders is seen as a positive signal, while heavy selling might raise concerns.

Stakeholder Impact

• Shareholders may react to the reported transactions, potentially influencing the stock price in the short term.
• The transactions could influence employee morale, depending on how they are perceived.

Key Dates